Bladder Cancer: Positive Signs For Tecentriq, Seattle Genetics Shines
Executive Summary
Middling data for Roche’s IO plus chemo combo were presented at ESMO, while Seattle's rival drug antibody conjugate posted an impressive Phase I response rate.
You may also be interested in...
Padcev Sales Exceed Expectations As Seattle Genetics Pursues Earlier Indications
The bladder cancer drug delivered $34.5m in its first full quarter of sales – four times analyst consensus for Q1 – and Padcev’s market may grow rapidly based on results from ongoing studies.
Eight Talking Points From ESMO
Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.
Ten Strategies For Success In Antibody-Drug Conjugate Development
The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?